CSF2RA gene-corrected macrophages(University of South Florida)

N/A

Report date: 2023/03/10 20:00:33

Base Information

Drug NameCSF2RA gene-corrected macrophages(University of South Florida)
Drug Alias NameAutologous bone marrow CD34+ cell-derived, CSF2RA lentiviral vector-transduced macrophages(University of South Florida)Lentiviral-mediated CSF2RA Gene Transfer/Pulmonary Macrophage Transplantation Therapy(University of South Florida)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Macrophages therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived +[4] 
Mechanisms of ActionGranulocyte-macrophage colony-stimulating factor receptor subunit alpha inhibitors
TargetsGranulocyte-macrophage colony-stimulating factor receptor subunit alpha
Therapy Area/IndicationsPulmonary Alveolar Proteinosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRussian Academy Of Medical Sciences
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of South Florida
Inactive CompaniesN/A
Active IndicationsPulmonary Alveolar Proteinosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A